Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 415 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 New on NCI’s Websites for March 2025 March 13, 2025 For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored July 16, 2021 EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... April 7, 2022 Load more HOT NEWS New Combination of Old Drugs Improves Survival in Patients with Prostate... Wales: 4 in 10 with possible cancer symptoms didn’t contact GP Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases
